Program
TQH3906
A development code. Also written as “TQH3906 capsules”, “TQH3906 capsule” and “TQH3906 Capsule”.
In Sino Biopharmaceutical's pipeline, TYK2抑制剂
. Its studies are mostly in Psoriasis · Arthritis, Psoriatic · Lupus Erythematosus, Systemic · Inflammatory Bowel Diseases, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 64 open or running | phase 3since Jul 21, 2026 | Jan 21, 2024 | Jul 2027phase 1 · NCT06754891 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQH3906
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 21, 2024First study: phase 1 study in PsoriasisFirst studyNCT06230588 · 96 enrolled · China
- Aug 5, 2024Phase 2 study in Plaque PsoriasisNCT06542614 · 209 enrolled · China
- Dec 25, 2024Phase 1 study in Inflammatory Bowel DiseasesNCT06754891 · 135 planned · China
- Jan 29, 2026Phase 2 study in Arthritis, PsoriaticNCT07406035 · 156 planned · China
- Mar 28, 2026Phase 2 study in Lupus Erythematosus, SystemicNCT07509892 · 198 planned · China
- Jul 21, 2026Phase 3 study in PsoriasisPhase 3 reachedNCT07724366 · 400 planned · China
Ahead
- Jul 2027Primary completion: phase 1 study in Inflammatory Bowel DiseasesNCT06754891
- Aug 2027Primary completion: phase 2 study in Arthritis, PsoriaticNCT07406035
- Sep 2027Primary completion: phase 3 study in PsoriasisNCT07724366
- Nov 2027Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT07509892
TargetBeta
“TYK2抑制剂”the company's pipeline, read by Claude · source
Other programs on TYK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ruxolitinibrule | Incyte | phase 4 | 95 |
| tofacitinibrule | Pfizer | phase 4 | 94 |
| upadacitinibrule | AbbVie | phase 4 | 64 |
| deucravacitinibrule | Bristol-Myers Squibb | phase 4 | 60 |
| filgotinib maleaterule | Eisai | phase 4 | 2 |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 46 |
| brepocitinibrule | Pfizer | phase 3 | 25 |
| delgocitinibrule | LEO Pharma | phase 3 | 21 |
| D-2570rule | InventisBio | phase 3 | 13 |
| HS-10374 | Hansoh Pharmaceutical Group | phase 3 | 6 |
| FXS5626 | Fosun Pharma | phase 3 | 3 |
| TYK2 Inhibitorrule | usynova-pharmaceuticals-ltd | no phase | 1 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07724366Psoriasis · China | 3 | Recruiting | Sep 2027 | 400 |
| NCT07509892Lupus Erythematosus, Systemic · China | 2 | Recruiting | Nov 2027 | 198 |
| NCT07406035Arthritis, Psoriatic · China | 2 | Recruiting | Aug 2027 | 156 |
| NCT06754891Inflammatory Bowel Diseases · China | 1 | Recruiting | Jul 2027 | 135 |
| NCT06542614Plaque Psoriasis · China | 2 | Completed | Nov 3, 2025 | 209 |
| NCT06230588Psoriasis · China | 1 | Completed | Apr 27, 2025 | 96 |
How it is read
Names in the registry
- “TQH3906 capsules”, 2 entries
- “TQH3906 capsule”, 2 entries
- “TQH3906 Capsule”, 1 entry
- “24mg bid TQH3906 capsule”, 1 entry
- “32mg TQH3906 capsule”, 1 entry
Codes read as this program: TQH3906.
Conditions, from the studies’ own filings
- Psoriasis, 3 studies
- Arthritis, Psoriatic, 1 study
- Lupus Erythematosus, Systemic, 1 study
- Inflammatory Bowel Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.